Pharmaceutical

Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia

Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ quemliclustat (AB680) in Japan and Asian territories.

Jul 10, 2024 - 04:00
Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia
Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ quemliclustat (AB680) in Japan and Asian territories.
Read the original article

Tags:

Previous Article

SciRhom secures $70m for autoimmune diseases treatments

Next Article

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Q&A: What does it mean when a clinical trial is delayed? More than you think

Q&A: What does it mean when a clinical trial is delayed...

Apr 17, 2023

STAT+: Ted Love, BIO’s first Black board chair, aims to rehab biotech’s image in Washington

STAT+: Ted Love, BIO’s first Black board chair, aims to...

Jun 6, 2023

UnitedHealth’s rehab restrictions, Texas medical school drama, and health care’s biggest profits

UnitedHealth’s rehab restrictions, Texas medical school...

Jan 2, 2024